Europe’s medicines regulator added a rare nerve-degenerating disorder, Guillain-Barré syndrome, as a possible rare side effect from Johnson & Johnson’s Covid-19 vaccine after the European Medicines Agency reviewed 108 cases reported worldwide.

The EMA’s risk assessment committee recommended restrictions on the use of the broad-spectrum antibiotics.

The European Medicines Agency warned for the second time in 2016 that some of the top-selling hepatitis C treatments could reactivate hepatitis B in patients.